SYNCROSOME your dedicated partner for In Vivo Efficacy Studies has been accepted for a poster presentation at NeuroFrance 2019 (Marseille, France, 22-24 May) which is an International Meeting from Société des Neurosciences.
Thanks to its CNS expertise our CNS Study Monitor, Dr. Delphine Revy, will present several results on Symptomatic and biochemical assessment of an antidyskinetic compound in a L-DOPA induced Dyskinesias rat model.
A few words about Syncrosome:
Syncrosome is an Efficacy Characterization CRO and we offer relevant disease models, cutting-edge techniques and a comprehensive background of physiopathology to assist drug discovery companies.
We have developped and validated so far more than 15 disease models, and our flexible and human-sized organization can design and operate tailored experimental protocols to give you appropriate answers.
Our main activities consit in :
- Drug Efficacy Studiesin several therapeutic areas :
- Central Nervous Sytem,
- Cardiovascular and Metabolic disease,
Early bioavailibility and CNS-PKon rodents and non-rodents with a high competence in the study of the Blood Brain Barrier passage.